Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00836875
Other study ID # A1501080
Secondary ID
Status Terminated
Phase Phase 3
First received February 3, 2009
Last updated June 19, 2014
Start date May 2009
Est. completion date May 2013

Study information

Verified date June 2014
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.


Recruitment information / eligibility

Status Terminated
Enrollment 31
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria:

- Immunocompromised with clinically compatible illness.

- Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions).

- Diagnosis of infection due to Scedosporium or Fusarium species.

- Male and female from 2 to 17 years of age.

- Females with childbearing potential must have negative pregnancy test and be using appropriate contraception.

Exclusion Criteria:

- Allergy or hypersensitivity to the azole drugs.

- Female subjects who are pregnant or lactating.

- Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection.

- Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation.

- Significant liver, kidney or heart dysfunction.

- Not expected to survive for at least 5 days.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Voriconazole
All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy. Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator. Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.

Locations

Country Name City State
Canada Pfizer Investigational Site Calgary Alberta
Czech Republic Pfizer Investigational Site Brno
Czech Republic Pfizer Investigational Site Brno
Netherlands Pfizer Investigational Site Nijmegen
Poland Pfizer Investigational Site Wroclaw
Singapore Pfizer Investigational Site Singapore
Singapore Pfizer Investigational Site Singapore
Spain Pfizer Investigational Site Barcelona
Spain Pfizer Investigational Site Madrid
Thailand Pfizer Investigational Site Bangkok noi Bangkok
Thailand Pfizer Investigational Site Patumwan Bangkok
Thailand Pfizer Investigational Site Rajathevee Bangkok
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Los Angeles California
United States Pfizer Investigational Site Oakland California
United States Pfizer Investigational Site Pittsburgh Pennsylvania
United States Pfizer Investigational Site Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Canada,  Czech Republic,  Netherlands,  Poland,  Singapore,  Spain,  Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events (AEs) Baseline, daily while hospitalized, Days 7, 14, 28, 42, 84, and 114, at end of treatment, and up to 1 month post treatment Yes
Secondary Percentage of Participants With a Global Response of Success Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to <90% resolution of the radiological lesions attributed to IA at Baseline. Weeks 6 and End of Treatment (EOT; up to Week 12) No
Secondary All-Cause Mortality - Number of Participant Deaths Number of participant deaths reported at Week 6 and at EOT (up to Week 12). Week 6 and EOT (up to Week 12) Yes
Secondary Attributable Mortality - Number of Participant Deaths Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12). Weeks 6 and EOT (up to Week 12) Yes
Secondary Time to Death Baseline up to 1 month post treatment Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06028451 - ManagemEnt of Antifungal Drug in Invasive Aspergillosis:a Real-word Study
Completed NCT00163722 - A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients Phase 3
Completed NCT02394483 - Single Ascending Oral Dose Study of F901318 Phase 1
Completed NCT00404092 - Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis Phase 2
Completed NCT01128907 - Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients N/A
Recruiting NCT01386437 - Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Withdrawn NCT02912026 - Radiolabelled IV and Oral Metabolism Study of F901318 Phase 1
Withdrawn NCT03076905 - Pharmacokinetics of IV Formulation Phase 1
Withdrawn NCT03095547 - Drug/Drug Interactions With F901318 Phase 1
Completed NCT02737371 - Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects Phase 1
Active, not recruiting NCT00838643 - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) N/A
Terminated NCT04876716 - Azole-echinocandin Combination Therapy for Invasive Aspergillosis Phase 3
Recruiting NCT05101187 - Olorofim Aspergillus Infection Study Phase 3
Enrolling by invitation NCT02104479 - Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Not yet recruiting NCT05707832 - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Phase 3
Recruiting NCT06382922 - Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
Terminated NCT02396225 - Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration N/A
Recruiting NCT00843804 - Surveillance for Nosocomial Infections in Pediatric Cancer Patients N/A
Completed NCT00334412 - COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Phase 4
Completed NCT04550936 - Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis